Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors

Autor: Kévin Bernal, Charbel Touma, Chedi Erradhouani, Talía Boronat‐Belda, Lucas Gaillard, Sara Al Kassir, Hélène Le Mentec, Corinne Martin‐Chouly, Normand Podechard, Dominique Lagadic‐Gossmann, Sophie Langouet, François Brion, Anja Knoll‐Gellida, Patrick J. Babin, Iva Sovadinova, Pavel Babica, Karine Andreau, Robert Barouki, Jan Vondracek, Paloma Alonso‐Magdalena, Etienne Blanc, Min Ji Kim, Xavier Coumoul
Přispěvatelé: Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de l'Environnement Industriel et des Risques - INERIS (FRANCE), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III [Madrid] (ISC), Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) (U1211 INSERM/MRGM), Université de Bordeaux (UB)-Groupe hospitalier Pellegrin-Institut National de la Santé et de la Recherche Médicale (INSERM), Univ Rennes, Inserm, EHESP, Irset, UMR S1085, Masaryk University [Brno] (MUNI), Institute of Biophysics of the Czech Academy of Sciences (IBP / CAS), Czech Academy of Sciences [Prague] (CAS), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de l'Environnement Industriel et des Risques (INERIS), The authors would like to thank the OBERON project (https://oberon-4eu.com/), funded by the European Union's Horizon 2020 research and innovation programme under grant agreement no. 825712, INSERM, Université Paris Cité and INERIS. IS and PB thank the RECETOX Research Infrastructure (no. LM2018121) and the CETOCOEN EXCELLENCE project (no. CZ.02.1.01/0.0/0.0/17_043/0009632) financed by the Ministry of Education, Youth and Sports for supportive background. This work was supported from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 857560., European Project: 825712,H2020-EU.3.1.1. - Understanding health, wellbeing and disease,H2020-SC1-2018-Single-Stage-RTD,OBERON(2019), Jonchère, Laurent, An integrative strategy of testing systems for identification of EDs related to metabolic disorders - OBERON - - H2020-EU.3.1.1. - Understanding health, wellbeing and disease2019-01-01 - 2019-12-31 - 825712 - VALID
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: FEBS Letters
FEBS Letters, Wiley, 2022, ⟨10.1002/1873-3468.14465⟩
FEBS Letters, 2022, ⟨10.1002/1873-3468.14465⟩
ISSN: 0014-5793
1873-3468
Popis: International audience; The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic (in vivo, in vitro and in silico) toxicology have recently provided compelling evidence implicating the chemical environment in the pathogenesis of these diseases. In this review, we will describe the biological processes that contribute to the development of metabolic diseases targeted by metabolic disruptors, and will propose an integrated pathophysiological vision of their effects on several organs. With regard to these pathomechanisms, we will discuss the needs, and the stakes of evolving the testing and assessment of endocrine disruptors to improve the prevention and management of metabolic diseases that have become a global epidemic since the end of last century.
Databáze: OpenAIRE
Externí odkaz: